Back to Search Start Over

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities

Authors :
Lucía Trilla-Fuertes
Angelo Gámez-Pozo
Guillermo Prado-Vázquez
Andrea Zapater-Moros
Mariana Díaz-Almirón
Jorge M. Arevalillo
María Ferrer-Gómez
Hilario Navarro
Paloma Maín
Enrique Espinosa
Álvaro Pinto
Juan Ángel Fresno Vara
Source :
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Publication Year :
2019
Publisher :
BMC, 2019.

Abstract

Abstract Background Muscle-invasive bladder tumors are associated with a high risk of relapse and metastasis even after neoadjuvant chemotherapy and radical cystectomy. Therefore, further therapeutic options are needed and molecular characterization of the disease may help to identify new targets. The aim of this study was to characterize muscle-invasive bladder tumors at the molecular level using computational analyses. Methods The TCGA cohort of muscle-invasive bladder cancer patients was used to describe these tumors. Probabilistic graphical models, layer analyses based on sparse k-means coupled with Consensus Cluster, and Flux Balance Analysis were applied to characterize muscle-invasive bladder tumors at a functional level. Results Luminal and Basal groups were identified, and an immune molecular layer with independent value was also described. Luminal tumors showed decreased activity in the nodes of epidermis development and extracellular matrix, and increased activity in the node of steroid metabolism leading to a higher expression of the androgen receptor. This fact points to the androgen receptor as a therapeutic target in this group. Basal tumors were highly proliferative according to Flux Balance Analysis, which makes these tumors good candidates for neoadjuvant chemotherapy. The Immune-high group showed a higher degree of expression of immune biomarkers, suggesting that this group may benefit from immune therapy. Conclusions Our approach, based on layer analyses, established a Luminal group candidate for therapy with androgen receptor inhibitors, a proliferative Basal group which seems to be a good candidate for chemotherapy, and an immune-high group candidate for immunotherapy.

Details

Language :
English
ISSN :
14712407
Volume :
19
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.f7769092f4564a8fbd2ffab2de8da2f1
Document Type :
article
Full Text :
https://doi.org/10.1186/s12885-019-5858-z